Zoetis Inc. (NYSE:ZTS) Receives $215.17 Consensus Price Target from Brokerages

Shares of Zoetis Inc. (NYSE:ZTSGet Rating) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $215.17.

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. decreased their target price on Zoetis from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Monday, October 17th. Morgan Stanley lowered their target price on Zoetis from $264.00 to $248.00 and set an “overweight” rating for the company in a research note on Tuesday, November 15th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Thursday, November 3rd. The Goldman Sachs Group reduced their target price on Zoetis from $207.00 to $180.00 and set a “buy” rating on the stock in a report on Friday, November 4th. Finally, StockNews.com started coverage on Zoetis in a research report on Wednesday, October 12th. They set a “buy” rating on the stock.

Zoetis Stock Performance

Shares of ZTS opened at $161.95 on Friday. Zoetis has a 1 year low of $124.15 and a 1 year high of $206.25. The company has a market cap of $75.48 billion, a price-to-earnings ratio of 36.97, a price-to-earnings-growth ratio of 2.77 and a beta of 0.73. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.48 and a current ratio of 2.27. The firm has a fifty day moving average of $150.42 and a 200-day moving average of $157.15.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.03). The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.08 billion. Zoetis had a net margin of 25.82% and a return on equity of 48.41%. Zoetis’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.25 earnings per share. As a group, equities analysts anticipate that Zoetis will post 4.87 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be given a $0.375 dividend. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date is Thursday, January 19th. This is a positive change from Zoetis’s previous quarterly dividend of $0.33. Zoetis’s payout ratio is 29.68%.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently made changes to their positions in the business. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC bought a new position in Zoetis in the first quarter worth approximately $26,000. Psagot Value Holdings Ltd. Israel bought a new position in Zoetis in the third quarter worth approximately $25,000. EWG Elevate Inc. bought a new position in Zoetis in the fourth quarter worth approximately $27,000. Finally, McClarren Financial Advisors Inc. bought a new position in Zoetis in the third quarter worth approximately $31,000. Institutional investors own 90.23% of the company’s stock.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.